Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Polar Capital Holdings Plc

Polar Capital Holdings Plc boosted its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 7.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 730,000 shares of the biopharmaceutical company's stock after buying an additional 50,000 shares during the quarter. Polar Capital Holdings Plc owned approximately 0.41% of Insmed worth $50,399,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Park Avenue Securities LLC increased its position in shares of Insmed by 42.1% during the 4th quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company's stock valued at $549,000 after purchasing an additional 2,358 shares during the last quarter. Atomi Financial Group Inc. grew its position in shares of Insmed by 6.6% in the 4th quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company's stock worth $1,710,000 after buying an additional 1,526 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock worth $244,000 after acquiring an additional 183 shares in the last quarter. Avior Wealth Management LLC bought a new position in Insmed in the 4th quarter worth about $157,000. Finally, Blue Trust Inc. lifted its stake in shares of Insmed by 25.7% in the 4th quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company's stock worth $180,000 after purchasing an additional 503 shares during the period.

Analyst Ratings Changes

A number of research firms recently weighed in on INSM. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Monday, May 12th. UBS Group lowered their target price on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Finally, Jefferies Financial Group started coverage on shares of Insmed in a research note on Tuesday, May 13th. They issued a "buy" rating and a $105.00 target price for the company. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $94.63.

Insmed Stock Performance

INSM traded down $0.65 during trading on Tuesday, reaching $67.23. 774,994 shares of the company were exchanged, compared to its average volume of 2,319,713. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The firm has a 50 day moving average of $71.45 and a 200 day moving average of $73.16. The stock has a market cap of $12.25 billion, a P/E ratio of -12.03 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period last year, the business earned ($1.06) earnings per share. On average, sell-side analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $25,742,347.58. This represents a 5.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Martina M.D. Flammer sold 1,799 shares of the firm's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $67.53, for a total value of $121,486.47. Following the transaction, the insider now owns 84,797 shares of the company's stock, valued at $5,726,341.41. This trade represents a 2.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 125,211 shares of company stock valued at $8,837,158 over the last 90 days. 3.00% of the stock is owned by company insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.